Elucidating differences in the hepatotoxic potential of tolcapone and entacapone with DILIsym®, a mechanistic model of drug-induced liver injury

CPT: Pharmacometrics and Systems Pharmacology

Volumn 5, Issue 1, 2016, Pages 31-39

  Longo, D M ^a,b   Yang, Y ^a   Watkins, P B ^a,b   Howell, B A ^a,b   Siler, S Q ^a,b  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^b DILIsymVR Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTACAPONE; TOLCAPONE; ANTIPARKINSON AGENT; BENZOPHENONE DERIVATIVE; CATECHOL DERIVATIVE; NITRILE; NITROPHENOL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CELL RESPIRATION; DRUG EXPOSURE; DRUG RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER TOXICITY; MATHEMATICAL MODEL; OXIDATIVE PHOSPHORYLATION UNCOUPLING; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIMULATION; TOXICOLOGY; BIOLOGICAL MODEL; BLOOD; COMPUTER SIMULATION; DRUG EFFECTS; ENZYMOLOGY; LIVER; RISK FACTOR;

ALANINE TRANSAMINASE; ANTIPARKINSON AGENTS; BENZOPHENONES; CATECHOLS; COMPUTER SIMULATION; HUMANS; LIVER; MODELS, BIOLOGICAL; NITRILES; NITROPHENOLS; RISK FACTORS;

EID: 84956759639     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12053     Document Type: Article

References (29)

1. Watkins, P. COMT inhibitors and liver toxicity. Neurology 55, S51-52; discussion S53-56 (2000).
2. Benabou, R. & Waters, C. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease. Expert Opin. Drug Saf. 2, 263-267 (2003).
3. Olanow, C.W. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch. Neurol. 57, 263-267 (2000).
4. Olanow, C. & Watkins, P. Tolcapone: an efficacy and safety review (2007). Clin. Neuropharmacol. 30, (2007).
5. Rivest, J., Barclay, C.L. & Suchowersky, O. COMT inhibitors in Parkinson's disease. Can. J. Neurol. Sci. J. Can. Sci. Neurol. 26(suppl. 2), S34-S38 (1999).
6. Myllyla, V.V., Kultalahti, E.-R., Haapaniemi, H. & Leinonen, M. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur. J. Neurol. 8, 53-60 (2001).
7. Nissinen, E., Kaheinen, P., Penttila, K.E., Kaivola, J. & Linden, I.B. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Eur. J. Pharmacol. 340, 287-294 (1997).
8. Nadanaciva, S. et al. Assessment of drug-induced mitochondrial dysfunction via altered cellular respiration and acidification measured in a 96-well platform. J. Bioenerg. Biomembr. 44, 421-437 (2012).
9. Haasio, K., Koponen, A., Penttila, K.E. & Nissinen, E. Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur. J. Pharmacol. 453, 21-26 (2002).
10. Morgan, R.E. et al. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol. Sci. Off. J. Soc. Toxicol. 136, 216-241 (2013).
11. Fattinger, K. et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69, 223-231 (2001).
12. Morgan, R.E. et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol. Sci. Off. J. Soc. Toxicol. 118, 485-500 (2010).
13. Howell, B.A. et al. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym: A mechanistic, mathematical model of DILI. J. Pharmacokinet. Pharmacodyn. 39, 527-541 (2012).
14. Howell, B.A., Siler, S.Q. & Watkins, P.B. Use of a systems model of drug-induced liver injury (DILIsym(VR )) to elucidate the mechanistic differences between acetaminophen and its less-toxic isomer, AMAP, in mice. Toxicol. Lett. 226, 163-172 (2014).
15. Woodhead, J.L. et al. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J. Pharmacol. Exp. Ther. 342, 529-540 (2012).
16. Woodhead, J. L. et al. Mechanistic modeling reveals the critical knowledge gaps in bile acid-mediated DILI. CPT Pharmacomet. Syst. Pharmacol. 3, e123 (2014).
17. Woodhead, J.L. et al. Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury. Front. Pharmacol. 5, 240 (2014).
18. Shoda, L.K.M., Woodhead, J.L., Siler, S.Q., Watkins, P.B. & Howell, B.A. Linking physiology to toxicity using DILIsym(VR ), a mechanistic mathematical model of druginduced liver injury. Biopharm. Drug Dispos. 35, 33-49 (2014).
19. Yang, K., Woodhead, J.L., Watkins, P.B., Howell, B.A. & Brouwer, K.L. Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity. Clin. Pharmacol. Ther. 96, 589-598 (2014).
20. Yang, Y. et al. MITOsymVR : A mechanistic, mathematical model of hepatocellular respiration and bioenergetics. Pharm. Res. 32, 1975-1992 (2015).
21. Perez-Carreras, M. et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 38, 999-1007 (2003).
22. Vernon, G., Baranova, A. & Younossi, Z.M. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34, 274-285 (2011).
23. Brooks, D.J. Safety and tolerability of COMT inhibitors. Neurology 62, S39-S46 (2004).
24. Kaplowitz, N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4, 489-499 (2005).
25. Corsini, A. et al. Current challenges and controversies in drug-induced liver injury. Drug Saf. Int. J. Med. Toxicol. Drug Exp. 35, 1099-1117 (2012).
26. Haasio, K., Nissinen, E., Sopanen, L. & Heinonen, E.H. Different toxicological profile of two COMT inhibitors in vivo: The role of uncoupling effects. J. Neural Transm. Vienna Austria 1996 109, 1391-1401 (2002).
27. Acuna, G. et al. Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J. 2, 327-334 (2002).
28. Schapira, A.H.V. Mitochondrial dysfunction in Parkinson's disease. Cell Death Differ. 14, 1261-1266 (2007).
29. Hauser, D.N. & Hastings, T.G. Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol. Dis. 51, 35-42 (2013).